Loading...
Partnering2018-11-30T18:16:00+00:00

Our Partnering Strategy

SynCore Biotechnology Co., Ltd (SynCore) is a biopharmaceutical company focusing on creating values of the new drugs by R&D and integration of technology resources. We build reliable and comprehensive relationships with our international partners, in all forms of research and development, clinical development and trial, as well as medical distribution and marketing. In guarantees of stable and long-term profits through strategic alliance to enrich sustainable operating energy, SynCore is proactively seeking in-licensing/out-licensing opportunities and collaborators worldwide, together consolidating drug development and innovative biotechnology of disease treatment, dedicate to pursuit a better human health and society.

What We’re Looking for

SynCore dedicates in new drug development and value-adding of innovation technology, in the purpose of being responsible and ethical manner to the individual, the society, and the environment. Therefore we look forward to working closely with pharma/biotechs to achieve our goals together.

Our partnering aims involve:

  • Commercialization partner of  EndoTAG®-1 for Pancreatic cancer
  • Co-development partner of EndoTAG®-1 for  Pancreatic cancer in China and Japan
  • Co-development of EndoTAG®-1 in other indications (Triple negative Breast cancer & other Paclitaxel related cancer)
  • Expanding licensing territory of Veregen®(herbal ointment for external genital wart treatment)in Asia-Pacific region
  • Distributing ophthalmic medical devices for human use
  • Broadening medical devices distribution for veterinary use

Contact Us

Thank you for your interest in SynCore Biotechnology. Please contact us at BD@syncorebio.com . We appreciate to your comments and feedback.

Medigene is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. Medigene is focused on the research and development of innovative drugs to treat cancer and autoimmune diseases. Medigene is the first biotech company in Germany to generate income from products on the market, which is sold by partner companies. In 2011, SyncoreBio were granted for the developing, marketing and manufacturing rights of Veregen® in Taiwan.

MacuCLEAR Inc.™ is a Texas Corporation with a specialty clinical-stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. MacuCLEAR Inc.™ was formed in 2006 when it secured a worldwide license for a proprietary platform technology for treating and preventing the progression of dry Age Related Macular Degeneration (dryAMD) developed by George C.Y. Chiou, Ph.D. at Texas A&M University.

Y-YBAR is producing medical devices for the research in ophthalmology, based in Switzerland. Considering the steadily growing global medical device market, SyncoreBio and Y-YBAR decided to start the partnership on developing a future of ophthalmic medical device industry together.In 2016, SyncoreBio and Y-YBAR signed Cooperation and Development Agreement of New Choroidal Blood Flowmeter.

Epipole was founded in January 2011 with the express aim of building intellectual property in the application areas of image processing, 3D, and medical imaging. The epiCam® family of retinal video devices was launched in 2016. Following by the newly launched in 2017, the epiCam® V veterinary variant enabling high-quality fundus imaging of a variety of animals. SyncoreBio and Epipole signed an agreement with Epipole for the Taiwanese distribution rights of epiCam® products.

Mr. Tim Lee, Chairman and Chief Executive Officer, Sinphar Pharmaceutical Co., Ltd. was founded in 1977. The I-Lan factory fully benefits from the pure water and air quality of the ounty. In 1996, Sinphar became the first pharmaceutical manufacturer to receive the ational Award of Small and Medium Enterprises and ISO 9001 accreditation. Again, sinphar was the only pharmaceutical company to be awarded the National Biotechnology & Medical Care Award in both “Whole Pharmaceutical Factory” and “Pharmaceutical Product innovation” categories in 2002.

The National Health Research Institutes (NHRI) is a non-profit foundation established by the government in 1996. Scientists at the NHRI conduct mission-oriented medical research and investigate many aspects of the basic biomedical sciences, as well as specific diseases. These range from the common problems such as aging, cancer, infectious diseases, mental disorders, occupational diseases, to health policy. NHRI hope that the knowledge, experience, and facilities at the NHRI will become important resources to the whole nation in understanding, preventing, and curing diseases.